May 27, 2020
Seneca Biopharma Announces the Closing of its $5 Million Registered Direct Offering
May 22, 2020
Seneca Biopharma Reports Receipt of Warrant Exercise Proceeds
May 22, 2020
Seneca Biopharma Announces Pricing of $5 Million Registered Direct Offering Priced At-the-Market
Apr 09, 2020
Seneca Biopharma Announces Results of Meeting with FDA Regarding the Design of Phase 3 Trial for NSI-566 in ALS
Apr 03, 2020
Seneca Biopharma, Inc. Announces the Completion of Stem Cell Manufacturing Facility in China
Apr 01, 2020
Seneca Biopharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Apr 01, 2020
Seneca Biopharma Announces Executive Appointments and Key Promotion
Jan 22, 2020
Seneca Biopharma Announces Closing of Exercise of Warrants for $7.55 Million Gross Proceeds
Jan 17, 2020
Seneca Biopharma Announces Exercise of Warrants for $7.55 Million Gross Proceeds Priced At-the-Market
Jan 10, 2020
Seneca Biopharma Announces Presentations at Both Sachs Associates 3rd Annual Neuroscience Innovation Forum & Biotech Showcase(TM) 2020
Nov 14, 2019
Seneca Biopharma Reports Third Quarter 2019 Fiscal Results
Nov 01, 2019
Seneca Biopharma and Jiangsu QYuns Therapeutics Announce Development Plan for Potential Joint Pipeline at 7th China Renaissance Healthcare and Life Science Leadership Summit
Oct 30, 2019
Seneca Biopharma and QYuns Therapeutics Sign Term Sheet for Global Licensing of Novel Monoclonal Antibodies for Treating Auto-Immune Diseases
Oct 28, 2019
Seneca Biopharma to Present at the 7th China Renaissance Healthcare and Life Sciences Leadership Summit